India’s CDSCO approves generics of Favipiravir and Remdesivir for Covid-19 treatment

This article was originally published here

Following the approval from the drug regulator, Glenmark Pharmaceuticals has launched the generic version of oral antiviral drug Favipiravir under the brand name of FabiFlu. Favipiravir was developed

The post India’s CDSCO approves generics of Favipiravir and Remdesivir for Covid-19 treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply